Core Viewpoint - Analog Devices, Inc. has appointed Dr. Yoky Matsuoka to its Board of Directors, expanding the board to 11 members, effective January 20, 2026 [1][2]. Group 1: Appointment Details - Dr. Matsuoka is an executive officer at Panasonic Holdings, responsible for global innovation and new business [2]. - She has held significant roles at major technology companies, including Vice President at Google’s healthcare organization and Chief Technology Officer at Google/Nest [2]. - Dr. Matsuoka has a strong academic background, having been an endowed professor at Carnegie Mellon University and the University of Washington, focusing on AI, robotics, and neuroscience [3]. Group 2: Contributions and Recognition - Dr. Matsuoka's expertise in integrating hardware, software, and AI aligns with Analog Devices' mission to deliver meaningful human outcomes [3]. - She received the MacArthur Genius Award for her contributions to robotics and neuroscience and founded the YokyWorks Foundation to assist children with physical and learning challenges [3][4]. - In 2023, she was recognized on Forbes' 50 Over 50: Innovation list and Inc.'s Top Female Founders list [4]. Group 3: Company Overview - Analog Devices, Inc. is a global leader in semiconductors, focusing on bridging the physical and digital worlds [5]. - The company reported revenue exceeding $11 billion in FY25, emphasizing its role in driving advancements across various sectors, including healthcare, energy, and automation [5].

Core Insights - Alkermes is positioned for growth in 2026, building on accomplishments from 2025 to enhance its value creation potential [3][5] - The company is characterized as a profitable neuroscience firm with a late-stage candidate, indicating a strong foundation for future development [5] Company Overview - Alkermes is participating in the 44th Annual Healthcare Conference, showcasing its management team and strategic direction [2] - The CEO, Richard Pops, expressed excitement about the company's trajectory and future opportunities [3] Financial and Strategic Position - The company emphasizes its strong foundation for both near-term and long-term growth, highlighting its profitability and leadership in the neuroscience sector [5]

Core Insights - AbbVie generates significant revenue from its immunology franchise, particularly from the strong uptake of its blockbuster drugs, Skyrizi and Rinvoq, which have helped the company achieve top-line growth despite the loss of exclusivity for Humira three years ago [1][8] - The company is expected to report Q4 and full-year 2025 results on February 4, 2025, with investors keenly awaiting sales figures for Skyrizi and Rinvoq [1] Immunology Performance - Skyrizi and Rinvoq have been successfully launched across major indications previously covered by Humira, including a new indication for atopic dermatitis, and have shown strong performance in the inflammatory bowel disease (IBD) market, particularly for ulcerative colitis (UC) and Crohn's disease (CD) [2] - Sales estimates for Q4 2025 are projected at $4.87 billion for Skyrizi and $2.33 billion for Rinvoq, driven by strong demand in the IBD market and new indications [3][8] Expansion into Other Therapeutic Areas - AbbVie is expanding its presence in neuroscience and oncology, with growth in neuroscience supported by the uptake of oral migraine therapies, Ubrelvy and Qulipta [4] - In oncology, AbbVie has broadened its portfolio to include solid tumors, led by newer assets such as Elahere and Emrelis [4] Competitive Landscape - The immunology market is highly competitive, with Johnson & Johnson (JNJ) as a key player, marketing blockbuster drugs Stelara and Tremfya, and focusing on Tremfya after Stelara lost U.S. patent exclusivity [5] - Eli Lilly (LLY) is also expanding its immunology presence with the FDA approval of Omvoh for UC, marking its first immunology drug approved for IBD in the U.S. [6] Financial Performance and Valuation - AbbVie shares have outperformed the industry year to date, trading at a P/E ratio of 15.50, which is lower than the industry average of 17.91 [7][9] - The bottom-line estimate per share for 2025 has slightly declined from $10.73 to $10.64, while estimates for 2026 have increased from $14.41 to $14.42 over the past 60 days [10]

Core Insights - AbbVie has established a significant neuroscience franchise, initially supported by Botox Therapeutic and Vraylar, now expanded to include Ubrelvy, Qulipta, and Vyalev [1][4] Sales Performance - Neuroscience segment sales represented over 17% of AbbVie's total revenues in the first nine months of 2025, driven by strong sales growth in Botox Therapeutic, Vraylar, Qulipta, and Ubrelvy, all showing double-digit increases year-over-year [2][9] - Vyalev generated $299 million in sales during the same period, contributing to the overall growth despite declines in older therapies like Duodopa [2] Future Projections - AbbVie anticipates neuroscience sales to reach $10.7 billion by the end of 2025, indicating a 19% growth compared to 2024 [3][9] - The company is preparing to enhance its neuroscience portfolio with new therapies, including tavapadon, a potential oral treatment for Parkinson's disease, which could launch later this year [4] Pipeline Expansion - AbbVie is heavily investing in expanding its neuroscience pipeline, including the acquisition of Gilgamesh Pharmaceuticals' bretisilocin, aimed at treating major depressive disorder [5] Competitive Landscape - Key competitors in the neuroscience space include Biogen and Johnson & Johnson, both diversifying their portfolios with novel therapies [6][7] Valuation and Market Performance - AbbVie shares have outperformed the industry over the past year, trading at a P/E ratio of 21.41, above the industry average of 19.26 and its five-year mean of 13.53 [8][11] - The Zacks Consensus Estimate for AbbVie's 2025 EPS remains steady at $10.64, with a slight increase for 2026 from $14.40 to $14.42 [13]

Open your hearts. Open your spirits to what you're going to hear today. Grab on to at least one idea because if we don't start spreading the ideas, who's going to.Ladies, have you ever felt that your voice was on mute. When I was 32, I walked into a room that was full of men sitting in chairs all dressed in dark brown boring suits. I could hear their quiet conversations, which told me I wasn't supposed to hear what they were saying.It was a polite tolerance at best. At the same time, I was really proud to b ...

YEAH. YEAH. Right now, just listening to my son's cries, my heart rate spikes, my pupils dilate, stress hormones flood my body.This reaction is ancient because the very survival of our species has depended upon our ability to hear that cry, interpret it, and respond. When we do this well, babies thrive. But when we don't, the cost lasts a lifetime.I'm a developmental cognitive neuroscientist and a mom of two. So, I've seen in my lab and in my living room how early moments of connection set the blueprint for ...

AI and Neuroscience Convergence - AI模型内部的数学对象与神经科学中大脑的数学对象相似，不同模型在不同数据集上训练时，会收敛到相同的底层表示，表明AI可能正在学习关于宇宙的深刻知识 [3][4] - 人工智能和大脑的工作方式比最初认为的更相似 [2] Brain-Computer Interface (BCI) Technology and Applications - Science 公司正在开发一种视网膜假体，该芯片植入眼睛后部，使无法识别面孔的年龄相关性黄斑变性患者能够再次阅读 [11][12] - 视网膜假体通过绕过视杆细胞和视锥细胞，将视觉信息传回大脑，使患者能够阅读整个视力表 [15][16] - BCI技术可能与医学并行发展，甚至超越医学，通过操纵、控制和增强大脑来延长寿命 [19] - BCI的近期应用是针对严重的医疗疾病的医疗设备，这些设备将获得付款人的报销 [38] Future of BCI and Human Augmentation - 预计在未来十年内，大脑边界可以被重划，从而改变大脑的起始和结束位置，以及个体的起始和结束位置 [8][9] - 通过将计算技术插入大脑，可能会创造出具有超越常人能力的新人类 [35] - 下一代BCI技术可能会使中风或其他损伤患者获得惊人的机会 [37] Challenges and Considerations - 医疗保健领域存在一个根本性的矛盾，即随着技术的进步，能够延长寿命和提高生活质量的技术越来越多，但医疗保健的资金却相对固定 [39][40] - 解决心血管疾病和癌症等难题可能可以通过直接连接大脑来避免 [21] - 将电极植入运动皮层后，患者可以在大约一个小时后开始玩电子游戏，这在医学领域产生了前所未有的效果 [18] - Prima 是一种 2mm x 2mm 的芯片，植入视网膜下，与带有摄像头和激光的眼镜配合使用，激光将红外光投射到植入物上，刺激双极细胞 [26][27]

Core Insights - AbbVie is a leading player in the immunology sector, driven by three major drugs: Skyrizi, Rinvoq, and Humira, which collectively contribute to nearly 50% of the company's revenue [1] - Following the loss of U.S. exclusivity for Humira in 2023, AbbVie has experienced a strong recovery, primarily due to the increasing sales of Skyrizi and Rinvoq [2][3] Sales Performance - The combined sales of Skyrizi and Rinvoq have increased by 53% year-over-year, reaching $18.5 billion [3][9] - AbbVie anticipates that the combined sales of these two drugs will exceed $25 billion by 2025 and surpass $31 billion by 2027 [4][9] Market Position and Growth Drivers - AbbVie has successfully launched Skyrizi and Rinvoq across major indications, including a new indication for atopic dermatitis, which has bolstered their market position [2][4] - The company is also expecting regulatory submissions for new indications for Rinvoq, which could add approximately $2 billion to peak-year sales [4] Competitive Landscape - AbbVie faces competition from Johnson & Johnson, which markets Stelara and Tremfya, and Eli Lilly, which has recently entered the immunology market with Omvoh [6][7] Valuation and Stock Performance - AbbVie shares are currently trading at a slight discount to the industry average, with a price/earnings (P/E) ratio of 16.31 compared to the industry's 16.91 [11] - The stock has outperformed the industry year-to-date [8]

Kako da zadržimo fokus i snagu u svetu prepunom prekidanja i pritisaka? Bogdan Mijović otkriva koliko nas zaista košta stres i kako male promene vraćaju ono najvrednije. ? Mozak pod pritiskom: cena stresa i kako da prođemo jeftinije – govor o skrivenim troškovima savremenog života i načinima da očuvamo vreme, energiju i mir. ||||| ENG: How do we keep our focus and strength in a world full of interruptions and constant pressure? Bogdan Mijovic sheds light on what stress really costs us and how small shifts c ...

Here is Tula Berkeley. [applause] I never feel more alive than when I'm on stage performing. Whether it be acting, singing, or dancing, the connection with my cast and crew, the magic in the room when the audience comes alive, it's unlike anything in the world, and I'm addicted to it.Whether as a very young child with dog ears dancing to how Much is that doggy in the window or belting at the top of my lungs with my favorite meadows Mustangs and Rock of Ages, there is no show too small and no challenge too g ...